OncLive TV

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Jared Weiss, MD, discusses ​the design of the phase 3 KRYSTAL-10 trial in KRAS G12C-mutated unresectable or metastatic colorectal cancer.

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

Georges Azzi, MD, discusses the rationale for the phase 3 CIRCULATE study in colorectal cancer.

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer. 

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Ruben A. Mesa, MD, discusses JAK inhibitors and other promising agents in the myelofibrosis therapeutic landscape.

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Danielle M. Brander, MD, discusses the role of achieving minimal residual disease negativity with venetoclax-based regimens in chronic lymphocytic leukemia.

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Omid Hamid, MD, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes therapy in melanoma.

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Tanios S. Bekaii-Saab, MD, FACP, discusses the promise of non–VEGF inhibitor platforms in hepatocellular carcinoma.

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.

Michael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer.

Mothaffar Fahed Rimawi, MD, discusses the promise of the phase 3 HER2CLIMB-02 trial in HER2-positive metastatic breast cancer.

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Mario Spaggiari, MD, discusses considerations for patients with colorectal cancer and liver metastases who have no surgical options.

Tatyana Feldman, discusses the efficacy of adding etoposide to brentuximab vedotin followed by brentuximab vedotin consolidation in patients with newly diagnosed, CD30-expressing peripheral T-cell lymphomas.